AbbVie’s etentamig meets dual primary endpoints in Phase 3 blood cancer study
AbbVie said its blood-cancer drug etentamig met dual primary endpoints in a Phase 3 study, including a significantly higher objective response rate and improvements in progression-free survival versus standard available therapies.
AbbVie said etentamig, a drug to treat blood cancer, met its dual primary endpoints in a Phase 3 study. The company said etentamig showed a significantly higher objective response rate and improved progression-free survival versus standard available therapies in patients with triple…